CoChat

Hereditary Retinoblastoma and Risk of Lung Cancer

Kleinerman, R. A. · 2000 · Journal of the National Cancer Institute
Cited by 76

The DOI matches its Crossref record.

Abstract

Patients who have survived hereditary retinoblastoma are at increased risk of dying of a sarcoma, a melanoma, or a brain tumor. The increased risk has been attributed to germline mutations in the retinoblastoma-1 (RB1) gene, which encodes the cell cycle regulatory protein pRb (1). However, the extent to which patients with hereditary retinoblastoma are at increased risk of dying of common epithelial cancers of adulthood, such as lung cancer, is unknown. Somatic mutations in the RB1 gene are known to contribute to the development of lung cancer (2,3), and evidence of increased risk of lung cancer in adult RB1 mutation carriers has been reported (4,5), but questions remain about the association between hereditary retinoblastoma and lung cancer risk (6). In our earlier follow-up studies of 1604 one-year survivors of retinoblastoma (1,7) followed for a median of 17 years, we did not detect an increased risk of lung cancer, but few patients had reached 40 years of age, when the incidence rates for most epithelial cancers begin to rise. After 7 additional years of follow-up, we have again assessed these patients' risk of dying of lung cancer. The cohort consists of 964 patients with hereditary retinoblastoma (60%) and 640 patients with nonhereditary retinoblastoma (40%) who were followed from 1 year after retinoblastoma diagnosis in 1914 through 1984 (Table 1). Patients with bilateral tumors or unilateral tumors with a family history of retinoblastoma were classified as having hereditary retinoblastoma. The earlier mortality study (1) was based on follow-up from 1925 through 1990. The Institutional Review Board of the National Institutes of Health (Bethesda, MD) approved this study, in which we linked the cohort with the National Death Index Plus to ascertain new deaths and causes of these deaths through December 31, 1997. Among the patients with hereditary retinoblastoma, 71 females and 68 males had survived to 40 years of age or more by the end of 1997. The standardized mortality ratio (SMR) for the period from 1925 through 1997 was calculated as the ratio of the observed number of deaths among the retinoblastoma patients to the expected number of deaths estimated from the appropriate U.S. age-, sex-, and calendar-year cause-specific death rates (8). Exact 95% confidence intervals (CIs) were computed, assuming that the number of deaths followed a Poisson distribution. After 7 additional years of follow-up, the risk of death from cancers other than retinoblastoma was higher for patients with hereditary retinoblastoma (observed = 129; expected = 2.75; SMR = 47 [95% CI = 39–56]) than for patients with nonhereditary retinoblastoma (observed = 10; expected = 2.63; SMR = 3.8 [95% CI = 1.8–7.0]) (Table 1). During the 7 additional years of follow-up, there were 50 new deaths in the entire cohort attributable to tumors other than retinoblastoma, predominantly cancers of the bone (13 cases), connective tissue (12 cases), and lung (five cases). Although one case of lung cancer had been reported previously in this cohort (1), subsequent examination of medical records indicates that this cancer, observed in a 12-year-old boy, was probably a metastatic osteosarcoma; therefore, it was excluded from our analyses. There was a statistically significantly elevated risk of death from lung cancer among patients with hereditary retinoblastoma (observed = 5; expected = 0.33; SMR = 15.2 [95% CI = 4.9–35]). It is interesting that two lung cancer deaths occurred in patients who received radiotherapy (SMR = 8.1 [95% CI = 1.0–29]) and three occurred in patients who did not (SMR = 35 [95% CI = 7.0–102]), because radiotherapy has been linked with lung cancer in other populations. No lung cancer deaths occurred among patients with nonhereditary retinoblastoma. Histology was available for four of the five lung cancers from the patients with hereditary retinoblastoma (Table 2). Two cancers were small-cell lung carcinomas, one cancer was a mixed small-cell/large-cell carcinoma, and one cancer was an adenocarcinoma. Several case series and case reports have provided suggestive evidence that lung cancer risk is increased in patients with hereditary retinoblastoma. A case report in 1972 (9) described a small-cell lung cancer in a 45-year-old male who had bilateral retinoblastoma. Among 27 adults who survived retinoblastoma from the Manchester Children's Tumour Registry, there were nine cancer deaths, including four lung cancer deaths in men at the ages of 47, 52, 54, and 56 years (4). Additional case reports noted small-cell lung cancers in a 55-year-old male patient with hereditary retinoblastoma (10) and in a 28-year-old male patient with hereditary retinoblastoma who smoked cigarettes (11). In addition, in a cohort of 4101 parents, grandparents, aunts, and uncles of British retinoblastoma patients that included 117 RB1 mutation carriers (retinoblastoma survivors or unaffected carriers), the lung cancer SMR for these RB1 mutation carriers was 15

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/92.24.2037

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 76

Metadata

Authors
Kleinerman, R. A.
Venue
Journal of the National Cancer Institute
Published
2000-12-20
Volume
92
Issue
24
Pages
2037-2039
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2166320539
Cited by
76
References
0
FWCI
1.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hereditary Retinoblastoma and Risk of Lung Cancer. https://app.cochat.ai/papers/10.1093/jnci/92.24.2037
The paper
Kleinerman, R. A. (2000). Hereditary Retinoblastoma and Risk of Lung Cancer. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/92.24.2037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.